Gri Bio Etf Net Income
| GRI Etf | USD 2.39 0.06 2.45% |
As of the 11th of February 2026, GRI Bio retains the Risk Adjusted Performance of (0.24), coefficient of variation of (318.05), and Market Risk Adjusted Performance of 9.93. GRI Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the entity's future prices.
GRI Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing GRI Bio's valuation are provided below:Market Capitalization 3.5 M | Earnings Share (121.80) |
Understanding GRI Bio requires distinguishing between market price and book value, where the latter reflects GRI's accounting equity. The concept of intrinsic value - what GRI Bio's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push GRI Bio's price substantially above or below its fundamental value.
Please note, there is a significant difference between GRI Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if GRI Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, GRI Bio's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
GRI Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to GRI Bio's etf what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of GRI Bio.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in GRI Bio on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding GRI Bio or generate 0.0% return on investment in GRI Bio over 90 days. GRI Bio is related to or competes with CNS Pharmaceuticals, Jaguar Animal, Silo Pharma, Biodexa Pharmaceticals, Abpro Holdings, InMed Pharmaceuticals, and Can Fite. The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses... More
GRI Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure GRI Bio's etf current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess GRI Bio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.32) | |||
| Maximum Drawdown | 77.14 | |||
| Value At Risk | (20.75) | |||
| Potential Upside | 11.88 |
GRI Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for GRI Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as GRI Bio's standard deviation. In reality, there are many statistical measures that can use GRI Bio historical prices to predict the future GRI Bio's volatility.| Risk Adjusted Performance | (0.24) | |||
| Jensen Alpha | (3.57) | |||
| Total Risk Alpha | (4.78) | |||
| Treynor Ratio | 9.92 |
GRI Bio February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.24) | |||
| Market Risk Adjusted Performance | 9.93 | |||
| Mean Deviation | 7.85 | |||
| Coefficient Of Variation | (318.05) | |||
| Standard Deviation | 11.43 | |||
| Variance | 130.64 | |||
| Information Ratio | (0.32) | |||
| Jensen Alpha | (3.57) | |||
| Total Risk Alpha | (4.78) | |||
| Treynor Ratio | 9.92 | |||
| Maximum Drawdown | 77.14 | |||
| Value At Risk | (20.75) | |||
| Potential Upside | 11.88 | |||
| Skewness | (1.70) | |||
| Kurtosis | 6.53 |
GRI Bio Backtested Returns
GRI Bio holds Efficiency (Sharpe) Ratio of -0.34, which attests that the entity had a -0.34 % return per unit of risk over the last 3 months. GRI Bio exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out GRI Bio's Market Risk Adjusted Performance of 9.93, coefficient of variation of (318.05), and Risk Adjusted Performance of (0.24) to validate the risk estimate we provide. The etf retains a Market Volatility (i.e., Beta) of -0.36, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning GRI Bio are expected to decrease at a much lower rate. During the bear market, GRI Bio is likely to outperform the market.
Auto-correlation | 0.91 |
Excellent predictability
GRI Bio has excellent predictability. Overlapping area represents the amount of predictability between GRI Bio time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of GRI Bio price movement. The serial correlation of 0.91 indicates that approximately 91.0% of current GRI Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.91 | |
| Spearman Rank Test | 0.77 | |
| Residual Average | 0.0 | |
| Price Variance | 4.33 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, GRI Bio reported net income of (11.96 Million). This is much lower than that of the Biotechnology family and significantly lower than that of the Health Care category. The net income for all United States etfs is notably higher than that of the company.
GRI Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GRI Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of GRI Bio could also be used in its relative valuation, which is a method of valuing GRI Bio by comparing valuation metrics of similar companies.GRI Bio is currently under evaluation in net income as compared to similar ETFs.
GRI Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GRI Bio's current stock value. Our valuation model uses many indicators to compare GRI Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GRI Bio competition to find correlations between indicators driving GRI Bio's intrinsic value. More Info.GRI Bio is rated # 2 ETF in price to earning as compared to similar ETFs. It is rated below average in price to book as compared to similar ETFs fabricating about 0.02 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for GRI Bio is roughly 40.11 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GRI Bio's earnings, one of the primary drivers of an investment's value.Fund Asset Allocation for GRI Bio
The fund invests 99.63% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides GRI Bio's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors for a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will manage securities in the fund's portfolio as market conditions and the fund's objectives change.
GRI Fundamentals
| Return On Equity | -2.38 | ||||
| Return On Asset | -1.04 | ||||
| Current Valuation | (4.66 M) | ||||
| Shares Outstanding | 1.45 M | ||||
| Shares Owned By Insiders | 3.74 % | ||||
| Shares Owned By Institutions | 0.33 % | ||||
| Number Of Shares Shorted | 700.75 K | ||||
| Price To Earning | 23.35 X | ||||
| Price To Book | 0.58 X | ||||
| EBITDA | (11.97 M) | ||||
| Net Income | (11.96 M) | ||||
| Cash And Equivalents | 183.82 M | ||||
| Cash Per Share | 0.30 X | ||||
| Total Debt | 71 K | ||||
| Debt To Equity | 1.23 % | ||||
| Current Ratio | 5.23 X | ||||
| Book Value Per Share | 12.07 X | ||||
| Cash Flow From Operations | (10.19 M) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (121.80) X | ||||
| Target Price | 644.0 | ||||
| Beta | -1.23 | ||||
| Market Capitalization | 3.54 M | ||||
| Total Asset | 8.67 M | ||||
| Retained Earnings | (51.7 M) | ||||
| Working Capital | 5.95 M | ||||
| Current Asset | 1.22 B | ||||
| Current Liabilities | 243.82 M | ||||
| One Year Return | 12.82 % | ||||
| Three Year Return | 8.99 % | ||||
| Five Year Return | 5.20 % | ||||
| Ten Year Return | 8.79 % | ||||
| Net Asset | 8.67 M | ||||
| Last Dividend Paid | 0.51 | ||||
| Equity Positions Weight | 99.63 % |
About GRI Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GRI Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GRI Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GRI Bio based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.